This study is for adults 18 or older with skin symptoms from cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE). CLE and SLE are conditions where the immune system attacks the skin, causing rashes or sores. Participants must have a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) score of at least 8, meaning their skin condition is active. The study will test a medicine called PF-06823859 to see if it helps improve skin symptoms.
About 48 people will join, with 32 receiving the medicine and 16 receiving a placebo (a treatment with no active drug) through an intravenous (IV) infusion, which means the medicine is given directly into a vein. The study lasts about 65 weeks, including various treatment and follow-up periods. Initially, all receive treatment every four weeks, then every eight weeks. Participants will have a last follow-up visit at week 60.
Key Points:
- The study lasts 65 weeks, with regular visits.
- Treatment involves IV infusions of either the study drug or placebo.
- Participants need to comply with study procedures, like skin biopsies.